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Abstract
Object—The Carotid Occlusion Surgery Study (COSS) was conducted to determine if STA-
MCA bypass, when added to best medical therapy, would reduce subsequent ipsilateral stroke in 
patients with complete ICA occlusion and an elevated OEF in the cerebral hemisphere distal to the 
carotid occlusion. A recent publication reported the methodology of COSS in detail and briefly 
outlined the major findings of the trial.29 The surgical results of COSS are described in detail in 
this report.
Methods—The Carotid Occlusion Surgery Study (COSS) was a parallel group, prospective, 1:1 
randomized, open-label, blinded-adjudication treatment trial. Participants with angiographic 
confirmed complete occlusion of the ICA causing either a transient ischemic attack (TIA) or 
ischemic stroke within 120 days and hemodynamic cerebral ischemia demonstrated by an 
increased oxygen extraction fraction (OEF) measured by positron emission tomography (PET) 
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were randomized to either surgical or medical treatment. The surgical patients underwent a STA-
MCA cortical branch anastomosis. One hundred and ninety-five patients were randomized: 97 to 
the surgical group and 98 to the medical group.
Results—In the intention-to-treat analysis, the two-year rates of the primary endpoint were 0.210 
for the surgical group and 0.227 for the medical group (p=0.78, log rank). Fourteen (15%) of the 
93 patients who had an STA-MCA arterial bypass had an endpoint ipsilateral hemispheric stroke 
in the 30 day peri-operative period, 12 within two days. The STA-MCA arterial bypass patency 
rate was 98% at the 30 day post-operative visit and 96% at the last follow-up examination. STA-
MCA arterial bypass markedly improved, although it did not normalize, the level of elevated OEF 
in the symptomatic cerebral hemisphere. Five operated patients and one non-operated patient in 
the surgical group had an endpoint ipsilateral hemispheric stroke after the 30 day peri-operative 
period. No baseline characteristics or intra-operative variables were identified that permitted the 
identification of those who would experience a procedure related stroke.
Conclusions—In spite of excellent bypass graft patency and improved cerebral hemodynamics, 
STA-MCA anastomosis did not provide an overall benefit on ipsilateral two-year stroke 
recurrence, mainly due to a much better than expected stroke recurrence rate (22.7%) in the 
medical group in the trial, but also because of a significant peri-operative stroke rate (15%).
Keywords
symptomatic occluded internal carotid artery; superficial temporal artery-middle cerebral artery 
anastomosis; impaired cerebral hemodynamics; oxygen extraction fraction; randomized trial
Introduction
Complete occlusion of the internal carotid artery (ICA) by atherosclerotic disease causes 
approximately 15-25% of ischemic strokes in the carotid artery distribution. Patients treated 
with medical therapy have a risk of recurrent stroke of 7-10% per year for all stroke and 
5-8% per year for ipsilateral ischemic stroke during the first two years following ICA 
occlusion. 17,18,20,21 ICA occlusion causes an estimated 61,000 first-ever strokes per year in 
the United States1,6,22,26,37,39 an incidence more than twice the annual occurrence of 
ruptured intracranial aneurysms.5 Superficial temporal artery-middle cerebral artery (STA-
MCA) anastomosis was developed to improve hemodynamics distal to an occluded 
artery.12,38,41 The International Study of Extracranial-to-Intracranial Arterial Anastomosis 
(STA-MCA bypass trial) tested the usefulness of STA-MCA bypass surgery as a 
prophylaxis against stroke.13 STA-MCA bypass was not effective in preventing subsequent 
stroke as compared to best medical therapy in any group of patients, including the 808 
patients with symptomatic complete occlusion of the ICA. Based on the results of this trial, 
extracranial-intracranial (EC-IC) arterial bypass was generally abandoned as a treatment for 
symptomatic complete ICA occlusion. Following the trial, several groups criticized the 
results on multiple grounds2,8,36 (Ausman-1986, Day-1986, Sundt-1987), , including the 
inability to identify and separately analyze a subgroup of patients with impaired cerebral 
hemodynamics due to occlusive cerebrovascular disease in whom surgical revascularization 
might be more beneficial.8
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Since then, advances in neuroimaging have made it possible to determine the hemodynamic 
effects of ICA occlusion in individual patients.9,17,20,40 The strongest evidence for an 
association between cerebral hemodynamic impairment and stroke was provided by the St. 
Louis Carotid Occlusion Study (STLCOS).17 This blinded prospective study found that 
severe hemodynamic failure, manifested by an elevated oxygen extraction fraction (OEF) in 
the cerebral hemisphere distal to a complete ICA occlusion, was an independent predictor of 
subsequent stroke in symptomatic medically treated patients. STA-MCA arterial bypass 
surgery has been shown to improve cerebral hemodynamics distal to an occluded 
ICA .4,15,16,27,28,33
The Carotid Occlusion Surgery Study (COSS) was a parallel group, prospective, 1:1 
randomized, open-label, blinded-adjudication treatment trial designed to test the hypothesis 
that STA-MCA anastomosis, when combined with best medical therapy, could reduce by 40 
per cent the subsequent occurrence of ipsilateral ischemic stroke at two years in patients 
with recent symptomatic ICA occlusion and ipsilateral increased OEF measured by positron 
emission tomography (PET). The trial design and analysis and primary results have been 
previously reported.29 The primary endpoint point in the surgical group was (1) all stroke 
and death from surgery through 30 days post-operatively plus (2) ipsilateral hemispheric 
ischemic stroke within two years. The primary endpoint in the non-surgical group was (1) all 
stroke and death from randomization through 30 days plus (2) ipsilateral hemispheric 
ischemic stroke within two years. All primary endpoints were ipsilateral ischemic strokes. 
Based on an intent-to-treat analysis, two-year rates for ipsilateral ischemic stroke were 
21.0% (95% CI, 12.8% to 29.2%; 20 events) for the 97 participants in the surgical group and 
22.7% (95% CI, 13.9% to 31.6%; 20 events) for the 98 participants in the nonsurgical group 
(p=0.78, z-test); difference = 1.7% (95% CI, -10.4% to 13.8%).29
METHODS
Surgical Procedure
The EC-IC arterial bypass procedure used in the COSS trial was a standard STA-MCA 
cortical branch anastomosis.11,25,30,41 If the STA was not suitable for anastomosis to the 
MCA, the occipital artery (OA) could be used in place of the STA. All surgical patients 
were placed on 81 mg or 325 mg of aspirin daily prior to the bypass procedure. All other 
peri-operative issues, such as anticonvulsants, antibiotics, choice of anesthetic agents, 
intraoperative hemodynamic monitoring and peri-operative fluid loading were left to the 
discretion of the operating surgeon. The STA-MCA cortical branch anastomosis was done 
using the best STA branch and the best MCA cortical branch. Only one anastomosis was 
done. Patients with an “unsuitable” STA (diameter < 1 mm) were excluded from the study. 
Details of the surgical technique used for the STAMCA anastomosis, such as using running 
or interrupted 10-0 prolene or nylon sutures, a straight or elliptical incision in the MCA 
cortical branch, and preparation of the STA graft, were left to the discretion of the operating 
surgeon. During and immediately following the surgical procedure, data concerning 
anesthesia techniques, intraoperative blood pressures (BP), cerebral monitoring and 
technical aspects of the bypass procedure was recorded and saved for analysis. Following 
surgery, all patients were left on 81 mg or 325 mg of aspirin for at least 30 days. Thereafter, 
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when deemed appropriate by their neurosurgeon, patients were returned to the anti-
thrombotic treatment preferred by their physicians. Doppler ultrasound examination was 
used to determine post-operative STA-MCA bypass patency at follow-up visits.
Surgical Certification
Surgeons were certified for the study by: (1) attending an initial training workshop in St. 
Louis where videotape instruction and surgical practice of microvascular anastomosis was 
done on frozen cadaver heads and live rat carotid arteries, or (2) demonstrating at least 80% 
bypass graft patency and less than or equal to 10% stroke and death at one month in at least 
10 consecutive STA-MCA bypass surgeries. Provisional certification was issued for those 
with less than 10 STA-MCA bypass cases available for review to perform a STA-MCA 
bypass operation on a patient enrolled in the trial under the observation of the principal 
neurosurgical investigator for the trial or a designated neurosurgeon with extensive 
STAMCA bypass experience.
Further Cerebrovascular Procedures
Both the non-surgical and surgical patients were prohibited from undergoing any additional 
surgical procedures following the STA-MCA arterial bypass that might alter cerebral 
hemodynamics or affect stroke risk, except for carotid endarterectomy performed for the 
development of symptomatic contralateral stenosis of the internal carotid artery.
Statistics
Categorical variables are displayed as counts and p-values are taken for generalized Fisher's 
exact tests. Continuous variables are displayed as means and standard deviations. 
Comparisons between groups used t-tests when the normality assumptions were valid. In 
three cases the normality assumption was not valid and the p-value was derived from a 
Wilcoxon rank sum test. These instances were noted in the tables.
Results
Thirty different surgeons performed 92 STA-MCA bypasses and 1 OA-MCA bypass at a 
median 6 days (interquartile range (IQR) 1-13) days following randomization to the surgical 
group. Four participants randomized to the surgical group did not undergo surgery. No 
strokes occurred during the time between randomization and surgery. The bypass patency 
rate was excellent, with a 98% patency rate (88/90 patients with patency data) at the 30 day 
post-operative visit. One patient died in the peri-operative period and graft patency data was 
not recorded in two other patients at the 30 day follow-up visit. At the last follow-up visit 
that assessed STA-MCA arterial bypass patency (mean 605 (±270 SD) days, range 28-1596 
days), the graft patency rate was 96% (86/90 patients with patency data). The mean OEF 
ratio in the surgical group improved from 1.258 at baseline to 1.109 at the 30-60 day post-
operative repeat PET scan (data from 87 participants). In a previous study, the upper limit of 
the OEF ratio calculated by similar methods in 18 normal subjects was 1.062.17 Twenty-
nine per cent (25/87) of the post-operative COSS PET scans were within the normal range.
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Fourteen (15%) of the 93 patients who had a STA-MCA arterial bypass had an endpoint 
ipsilateral hemispheric stroke in the 30 day peri-operative period. Twelve of the 14 peri-
operative ipsilateral hemispheric strokes occurred within the first 2 days following surgery. 
The other two occurred at 5 and 15 days after surgery. The occurrence of 2 strokes more 
than 2 days after surgery, but within 30 days, was identical to that observed in the non-
surgical group of 98 patients who had 2 ipsilateral strokes within 30 days of randomization.
Of the 14 strokes occurring within the 30 day peri-operative period, two were disabling at 
last follow-up (Barthel index > 12) and one was fatal. The patient who died in the post-
operative period had two ipsilateral strokes on the day of surgery, a vertebrobasilar artery 
distribution stroke on the first postoperative day (POD) and died on POD 4. The bypass was 
felt to be patent during the surgical procedure. Another patient had a post-operative 
ipsilateral stroke on the day of surgery. This bypass was also thought to be patent during the 
procedure, but the graft was occluded at the 30 day follow-up visit. The bypass was not 
patent at the completion of surgery in a third patient. This patient had an ipsilateral stroke on 
POD 1. Thus, the STA-MCA bypass was patent at the 30 day follow-up visit in 11 of the 14 
patients who had an ipsilateral hemispheric stroke in the 30 day post-operative period. The 
bypass was patent at last follow-up in the two patients who had a disabling ipsilateral 
hemispheric stroke in the peri-operative period. In 2 of the patients who had an ipsilateral 
hemispheric stroke in the 30 day peri-operative period other serious adverse events occurred 
during this time period (Table 1). One of the patients with a peri-operative ipsilateral 
hemispheric stroke also had an episode of hypoglycemia on POD 2, a deep venous 
thrombosis (DVT) on POD 6, an episode of atrial fibrillation/flutter on POD 9, a pulmonary 
embolus on POD 9, and a non-fatal cardiac tamponade on POD 14. A second patient with a 
peri-operative ipsilateral hemispheric stroke was found to have a small asymptomatic 
subdural hematoma and significant anemia on POD 3.
Twelve additional patients who did not have a 30 day peri-operative stroke had serious 
adverse events reported in the peri-operative period. (Table 1) Among these events were 
TIA's that occurred in 4 patients on POD 1, 7, 8 and 9 respectively. Three of these TIA's 
were reported as ipsilateral hemispheric strokes by the clinical sites, but they were later 
adjudicated as TIA's. Two of the 12 patients had a subdural hematoma (POD 21 and 26). 
The subdural hematoma found on POD 26 required surgical drainage. This patient also had a 
post-operative ipsilateral hemispheric stroke on POD 52. Other events in these 12 patients 
included a significant myocardial infarction on POD 0, severe respiratory distress on POD 0, 
one wound infection, one episode of severe hypotension, and a seizure in 2 patients.
The surgical certification method and the 30-day post-op stroke rate in the 30 surgeons who 
operated in COSS are outlined in Table 2. Fifteen of the 30 surgeons in the trial were 
certified by attending the initial training workshop. They performed 64 STA-MCA arterial 
bypasses in the trial with 11 (17 %) peri-operative ipsilateral strokes. Thirteen surgeons 
were certified by submitting data on 10 or more consecutive STA-MCA arterial bypasses 
that met the criteria listed above. In the trial they performed 24 STA-MCA arterial bypasses 
with 3 (13 %) peri-operative ipsilateral strokes. Only 2 surgeons in the trial had provisional 
certification, and they performed 5 STA-MCA arterial bypasses with no peri-operative 
strokes. Thus, there was no significant difference in the method of surgical certification for 
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the trial and the incidence of peri-operative strokes (p= .91). Seventeen of the 30 surgeons in 
the trial provided self-reported data for 292 EC-IC arterial bypasses for the grant submission 
to the National Institutes of Health for funds to conduct the study. Twenty-seven (9.2%) of 
these 292 patients had a stroke or died in the 30 day post-operative period. The same 17 
surgeons in the COSS trial performed 72 STA-MCA arterial bypasses with 8 (11.1 %) 
patients having an ipsilateral stroke in the peri-operative period, which was not significantly 
different from their pre-COSS experience (p=.655).
Since the peri-operative stroke rate negated any net benefit of the bypass surgery, we sought 
to identify factors that would predict peri-operative stroke occurrence. We performed this 
analyses for the 12 strokes that occurred within two days, since these were the most likely to 
be directly related to surgery, and the additional two strokes within 30 days of surgery were 
the same number as occurred in the non-surgical group within 30 days of randomization. 
Even though this type of analysis is hazardous because of the increase in false positive rate 
due to the large number of variables analyzed, we found no baseline or intra-operative 
variables that were different at the .05 level between those who experienced a stroke within 
two days of surgery and those who did not (Tables 3, 4A and 4B).
Five operated patients had an endpoint ipsilateral hemispheric stroke after the 30 day peri-
operative period. (One non-operated patient had an endpoint ipsilateral hemispheric stroke 
within the two-year follow-up period). In all five of these operated patients, the STA-MCA 
bypass was documented as patent following the surgical procedure and prior to the stroke. In 
4 of these patients, the bypass was documented as still patent following the stroke. There 
was no information recorded about bypass patency following the stroke in the other patient. 
Thus, in the 19 patients who had a primary endpoint ipsilateral hemispheric stroke after 
surgery, the bypass was documented as patent in 15 of the patients following the stroke. 
Two additional patients who underwent successful STA-MCA bypasses had strokes in the 
cerebral hemisphere contralateral to the symptomatic occluded carotid artery. Both patients 
had less than 50% stenosis of the contralateral carotid artery at the time of randomization, 
and their bypasses were patent at the last follow-up. In one patient, the stroke occurred on 
POD 556, and the other patient had contralateral hemispheric strokes on POD 279 and POD 
608.
Eliminating the 12 surgical patients who had peri-operative strokes within 2 days of surgery 
from the analysis, but retaining the two who had strokes between 2 and 30 days because 
these were identical in number to those occurring in the non-surgical group within 30 days 
of randomization, the rate of recurrent stroke for the remaining 81 patients in the surgical 
group was 9.0% compared to 22.7% in the non-surgical group.
Discussion
Prior to the start of the trial, there was concern that problems might be encountered during 
the study with STA-MCA bypass graft patency rates, as the procedure had not be done for 
patients with cerebral ischemia by most vascular neurosurgeons after the results of the STA-
MCA bypass trial were published in 1985. However, the STA-MCA arterial graft patency 
rates seen in the COSS trial of 96-98% were similar to the results obtained in the STA-MCA 
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bypass trial and other reported patient series. In the STA-MCA Bypass Trial, repeat cerebral 
angiography was carried out at a median time of 32 days post-op in 92% of the 652 STA-
MCA bypass trial patients who had a bypass procedure, and 96% of these patients had a 
patent STA-MCA anastomosis.13 In a report of 415 STA-MCA anastomoses performed at a 
single institution over an eight year period, a graft patency rate of 99% was achieved. 
Cerebral angiography was used to assess graft patency in the first 260 patients and Doppler 
velocity flow probe examination was performed in the remaining patients in this study.35 
The same investigators found a 96% graft patency rate confirmed by cerebral angiography in 
a separate analysis of 163 of these patients who had a STA-MCA anastomosis performed for 
cerebral ischemic symptoms due to complete internal carotid artery occlusion.19 Other case 
series of STA-MCA bypasses have reported graft patency rates of 90-96%.7,23,32,34,42
A literature review in 1978 of multiple case series reported an average permanent 
neurological morbidity of 2.4% and an average operative mortality of 4.3% in 376 STA-
MCA bypass procedures.32 There was an “other morbidity” of 13.6% in these patients. 
Other series of 100 to 415 patients from the same era of STA-MCA bypass surgery reported 
peri-operative stroke rates of 2-3.6% and peri-operative mortality rates of 1.2-3%.7,31,42 A 
peri-operative mortality of 2.1%, a permanent neurological impairment rate of 6.4% and a 
morbidity rate of 25.5% was found in a more recent series of 47 patient undergoing STA-
MCA bypass for cerebral ischemia symptoms34, while no operative mortality and a 3% peri-
operative stroke rate was reported in a contemporary study of 73 similar patients.23. 
However, in the multicenter, randomized STA-MCA bypass trial, 81 (12.2%) strokes in 663 
surgical patients occurred between randomization and 30 days post-op using an intent-to-
treat analysis of the surgical data. Sixteen of the peri-operative strokes occurred in patients 
randomized to surgery, but prior to a STA-MCA bypass procedure. The actual (on-
treatment) peri-operative stroke rate in this trial was 65 (9.8%) peri-operative strokes in 652 
STA-MCA bypass procedures, including 20 (3%) major strokes, with 4 (0.6%) of these 
strokes having a fatal outcome.3,13
There was a substantial occurrence of peri-operative non-stroke serious adverse events in 
COSS, including 2 patients who also had a peri-operative stroke and an additional 12 who 
did not. The rate of peri-operative non-stroke serious adverse events in COSS was similar to 
the occurrence of these events in previously published series of STA-MCA bypasses. Most 
of the reports of morbidities associated with STA-MCA bypass surgery have focused on 
ischemic neurologic deficits and have not listed other non-stroke peri-operative morbidity 
rates. However, a review in 1978 of 376 STA-MCA bypass procedures reported a peri-
operative “other morbidity” (non-cerebral ischemic) rate of 13.6%.32 Seven (2%) of 400 
patients7, 12 (3%) of 415 patients35, and 3 (6%) of 47 patients34 undergoing a STA-MCA 
bypass had a post-operative subdural hematoma/subdural hygroma requiring surgical 
drainage or subdural-peritoneal shunting. Scalp necrosis around the skin incision developed 
in 7%31 and 1.3%7 of patients in two series of STA-MCA bypasses. A pulmonary embolus 
occurred in 4 (6%) of 70 patients after a STA-MCA bypass.31.
In the EC-IC arterial bypass data submitted prior to the COSS trial, many of the EC-IC 
bypass procedures were not STA-MCA bypasses. Some of the EC-IC bypasses were high 
flow extracranial carotid artery-MCA anastomoses utilizing a saphenous vein graft or a 
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radial artery graft. Many of these self-reported procedures were done in patients undergoing 
either deliberate ICA or MCA occlusion for intracranial aneurysm treatment, intracranial 
tumor resection, or cerebral ischemia caused by moya-moya disease. Also, the majority of 
the patients were younger than the patients in the COSS trial. Inexperience with the STA-
MCA bypass procedure might account for the higher rate of peri-operative strokes seen in 
the COSS trial. However, the surgeons in COSS who provided the pre-trial data had similar 
results in COSS. Furthermore, the 30 day postoperative stroke of 15% in the COSS trial was 
not statistically different from the 9.8% peri-operative stroke rate seen performed in the 
STA-MCA bypass trial (p=0.136, Chi-square). An extensive analysis of multiple baseline 
characteristics and intra-operative variables did not demonstrate factors that would definitely 
identify patients with an increased risk of procedure related stroke.
Conclusions
The COSS trial confirmed that severe impairment of cerebral hemodynamics is an important 
risk factor for subsequent stroke in patients with symptomatic complete occlusion of the 
ICA. The study also confirmed the accuracy of PET measurements of OEF in identifying 
those patients with an occluded ICA at high risk for recurrent stroke due to poor collateral 
circulation.29 In the trial, STA-MCA arterial bypass markedly improved, although it did not 
normalize, the level of elevated OEF in the symptomatic cerebral hemisphere. After the 
second post-operative day, the rate of recurrent ipsilateral stroke for the remainder of the 
two-year follow-up period was only 9%. However, in spite of excellent bypass graft patency 
and improved cerebral hemodynamics, STA-MCA anastomosis did not provide an overall 
benefit on ipsilateral two-year stroke recurrence, mainly due to a much better than expected 
stroke recurrence rate (22.7%) in the medical group in the trial, but also because of a 
significant peri-operative stroke rate of 15%. These findings again confirm the hazard of 
relying on even the most carefully studied historical controls and re-affirm the necessity of 
performing randomized controlled trials to establish clinical efficacy.
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ICA internal carotid artery
IQR interquartile range
MCA middle cerebral artery
NIHSS National Institutes of Health Stroke Scale
OEF oxygen extraction fraction
PET positron emission tomography
OA occipital artery
OA-MCA occipital artery-middle cerebral artery
POD post-operative day
SS-QoL Stroke Specific Quality of Life
STA superficial temporal artery
STA-MCA superficial temporal artery-middle cerebral artery
STA-MCA bypass trial The International Study of Extracranial-to-Intracranial Arterial 
Anastomosis
STLCOS St. Louis Carotid Occlusion Study
TIA transient ischemic attack
References
1. Adams HP Jr, Bendixen BH, Leira E, Chang KC, Davis PH, Woolson RF, et al. A report of the Trial 
of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999; 53:122–125. [PubMed: 
10408547] 
2. Ausman JI, Diaz FG. Critique of the extracranial-intracranial bypass study. Surg Neurol. 1986; 
26:218–221. [PubMed: 3526597] 
3. Barnett HJM, Fox A, Hachinski V, Haynes B, Peerless SJ, Sackett D, et al. Further conclusions 
from the extracranial-intracranial bypass trial. Surgical Neurology. 1986; 26:227–235. [PubMed: 
3526599] 
4. Baron JC, Bousser MG, Rey A, Guillar A, Comar D, Castaigne P. Reversal of focal “misery-
perfusion syndrome” by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A 
case study with 15O positron emission tomography. Stroke. 1981; 12:454–459. [PubMed: 6976022] 
5. Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Eng J Med. 2006; 355:928–939.
6. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, et al. The Greater Cincinnati/
Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among 
blacks. Stroke. 1998; 29:415–421. [PubMed: 9472883] 
7. Chater N. Neurosurgical extracranial-intracranial bypass for stroke: with 400 cases. Neurol Res. 
1983; 5:1–9. [PubMed: 6140659] 
8. Day AL, Rhoton AL Jr. Little JR. The extracranial-intracranial bypass study. Surg Neurol. 1986; 
26:222–226. [PubMed: 3526598] 
9. Derdeyn CP, Grubb RL Jr, Powers WJ. Cerebral hemodynamic impairment: Methods of 
measurement and association with stroke risk. Neurology. 1999; 53:251–259. [PubMed: 10430410] 
Grubb et al. Page 9






















10. Derdeyn CP, Videen TO, Simmon NR, Yundt KD, Fritsch SM, Grubb RL Jr, et al. Count-based 
PET method for predicting ischemic stroke in patients with symptomatic carotid arterial occlusion. 
Radiology. 1999; 212:499–506. [PubMed: 10429709] 
11. Donaghy, RMP.; Yaşargil, MG. Microvascular Surgery. CV Mosby; St. Louis: 1967. p. 75-86.
12. Donaghy, RMP. History of microneurosurgery. In: Wilkins, RH.; Rengachary, SS., editors. 
Neurosurgery. 2nd Edition. Vol. I. McGraw-Hill; New York: 1996. p. 37-42.
13. EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of 
ischemic stroke. N Engl J Med. 1985; 313:1191–1200. [PubMed: 2865674] 
14. Flaherty ML, Flemming KD, McCelland R, Jorgensen NW, Brown RD Jr. Population-based study 
of symptomatic internal carotid artery occlusion: incidence and long-term follow-up. Stroke. 2004; 
35:e349–e352. [PubMed: 15232124] 
15. Gibbs JM, Wise RJ, Thomas DJ, Mansfield AO, Russell RW. Cerebral haemodynamic changes 
after extracranial-intracranial bypass surgery. J Neurol Neurosurg Psychiatry. 1987; 50:140150.
16. Grubb RL Jr, Ratcheson RA, Raichle ME, Kliefoth AB, Gado MH. Regional cerebral flow and 
oxygen utilization in superficial temporal-middle cerebral artery anastomosis patients. J 
Neurosurg. 1979; 50:733–741. [PubMed: 374689] 
17. Grubb RL Jr, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, et al. Importance of 
hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA. 1998; 280:1055–
1060. [PubMed: 9757852] 
18. Hankey GJ, Warlow CP. Prognosis of symptomatic carotid artery occlusion. Cerebrovascular 
Diseases. 1991; 1:245–256.
19. Jack CR Jr, Sundt TM Jr, Fode NC, Gehring DG. Superficial temporal-middle cerebral artery 
bypass: clinical pre- and postoperative angiographic correlation. J Neurosurg. 1988; 69:46–51. 
[PubMed: 3379476] 
20. Klijn CJM, Kappelle LJ, Tulleken CAF, van Gijn J. Symptomatic carotid artery occlusion: A 
reappraisal of hemodynamic factors. Stroke. 1997; 28:2084–2093. [PubMed: 9341723] 
21. Klijn CJ, van Buren PA, Kappelle LJ, Tulleken CAF, Eikelboom BC, Algra A, et al. Outcome in 
patients with symptomatic occlusion of the internal carotid artery. Eur J Vasc Endovasc Surg. 
2000; 19:579–586. [PubMed: 10873724] 
22. Mead GE, Murray H, Farrell A, O'Neill PA, McCollum CN. Pilot study of carotid surgery for acute 
stroke. Br J Surg. 1997; 84:990–992. [PubMed: 9240144] 
23. Mendelowitsch A, Taussky P, Rem JA, Gratzl O. Clinical outcome of standard 
extracranialintracranial bypass surgery in patients with symptomatic atherosclerotic occlusion of 
the internal carotid artery. Acta Neurochir (Wien). 2004; 146:95–101. [PubMed: 14963741] 
24. Ogasawara K, Ogawa A, Yoshimoto T. Cerebrovascular reactivity to acetazolamide and outcome 
in patients with symptomatic internal carotid or middle cerebral artery occlusion: a xenon-133 
single-photon emission computed tomography study. Stroke. 2002; 33:1857–1862. [PubMed: 
12105366] 
25. Peerless SJ, Gamache FW Jr, Hunter IG. Continuous suture method for microvascular 
anastomosis: Technical note. Neurosurgery. 1981; 8:695–698. [PubMed: 7024838] 
26. Pessin MS, Duncan GW, Mohr JP, Poskaner DC. Clinical and angiographic features of carotid 
transient ischemic attacks. N Eng J Med. 1977; 296:358–362.
27. Powers WJ, Martin WRW, Herscovitch P, Raichle ME, Grubb RL Jr. Extracranial-intracranial 
bypass surgery: Hemodynamic and metabolic effects. Neurology. 1984; 34:1168–1174. [PubMed: 
6611520] 
28. Powers WJ, Grubb, Raichle ME. Clinical results of extracranial-intracranial bypass surgery in 
patients with hemodynamic cerebrovascular disease. J Neurosurg. 1989; 70:61–67. [PubMed: 
2783342] 
29. Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP, for the COSS 
Investigators. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic 
cerebral ischemia: the Carotid Occlusion Surgery Study: A randomized trial. JAMA. 2011; 
306:1983–1992. [PubMed: 22068990] 
Grubb et al. Page 10






















30. Ratcheson, RA.; Grubb, RL, Jr. Superficial temporal-middle cerebral cortical artery anastomosis. 
In: Smith, RR., editor. Stroke and the Extracranial Vessels. Raven Press; New York: l984. p. 
255-263.
31. Reichman OH. Complications of cerebral revascularization. Clin Neurosurg. 1976; 23:319–335.
32. Samson DS, Boone S. Extracranial-intracranial (STA-MCA) arterial bypass: past performance and 
current concepts. Neurosurgery. 1978; 3:79–86. [PubMed: 683500] 
33. Samson Y, Baron JC, Bousser MG. Effects of extra-intracranial arterial bypass on cerebral blood 
flow and oxygen metabolism in humans. Stroke. 1985; 16:609–616. [PubMed: 3895592] 
34. Schick U, Zimmerman M, Stolke D. Long-term evaluation of STA-MCA bypass patency. Acta 
Neurochir (Wien). 1996; 138:938–943. [PubMed: 8890990] 
35. Sundt TM Jr, Whisnant JP, Fode NC, Piepgras DG, Houser OW. Results, complications, and 
follow-up of 415 bypass operations for occlusive disease of the carotid system. Mayo Clin Proc. 
1985; 60:230–240. [PubMed: 3982075] 
36. Sundt TM Jr. Was the international randomized trial of extracranial-intracranial arterial bypass 
representative of the population at risk? N Engl J Med. 1987; 316:814–816. [PubMed: 3547132] 
37. Thiele BL, Young JV, Chikos PM, Hirsch JH, Strandness DE Jr. Correlation of arteriographic 
findings and symptoms in cerebrovascular disease. Neurology. 1980; 30:1041–1046. [PubMed: 
7191494] 
38. Vilela MD, Newell DW. Superficial temporal artery to middle cerebral artery bypass: past, present 
and future. Neurosurg Focus. 2008; 24:E2. [PubMed: 18275297] 
39. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and 
recurrent) stroke. Stroke. 1999; 30:2523–2528. [PubMed: 10582972] 
40. Yamauchi H, Fukuyama H, Nagahama Y, Nabatame H, Ueno M, Nishizawa S, et al. Significance 
of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive 
diseases. J Nucl Med. 1999; 40:1992–1998. [PubMed: 10616876] 
41. Yaşargil, MG. Anastomosis between the superficial temporal artery and a branch of the middle 
cerebral artery. In: Yaşargil, MG., editor. Microsurgery Applied to Neurosurgery. George Thieme 
Verlag; Stuttgart: 1969. p. 105-115.
42. Zumstein B, Yaşargil MG. Verbesserung der hirndurchblutung durch mikrochirurgische bypass-
anastomosen. Schweiz Rundschau Med (Praxis). 1981; 70:1866–1873.
Grubb et al. Page 11











































Grubb et al. Page 12
Table 1
Peri-operative (30 Day) Non-stroke Serious Adverse Events
Event Number Of Events Post-op Day
TIA 4 1,7,8,9
Subdural hematoma 3 3,21,26
Wound infection 1 25
Myocardial infarction 1 0
Respiratory distress 1 0
Seizure 2 2,3
DVT 1 6
Pulmonary embolus 1 9
Atrial fibrillation/flutter 1 9
Cardiac tamponade 1 14
Severe hypotension 1 19
Hypoglycemia 1 2
Severe anemia 1 3
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Table 2
Surgical Certification and 30 Day Post-operative Stroke Rate
Method of Certification Number of Surgeons Number of Peri-operative Strokes
Initial Workshop Attendance 15 11/64 (17%)
Submission 10 Consecutive Cases 13 3/24 (13%)
Provisional certification 2 0/5 (0%)
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Table 3
Comparison of Baseline Characteristics Between Those Who Did and Did Not Experience A Stroke Within 
Two Days After Surgery
Perioperative Stroke Within 2 days
No Yes P value
Number 81 12






    Male (66) 57 9




    White (84) 72 12




    No (18) 15 3
    Yes (75) 66 9
Atrial Fibrillation, No. (%)
0.999
1
    No (92) 80 12




    No (16) 14 2




    No (73) 64 9




    Never (7) 6 1
    Former (54) 45 9




    No (83) 74 9
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Perioperative Stroke Within 2 days
No Yes P value
    No (48) 44 4
    Yes (43) 36 7




    TIA (42) 34 8




    Right (54) 49 5
    Left (39) 32 7
Entry Event to Randomization, mean(SD), days 73.8(38.5) 53.1(27.5)
0.093
3
Randomization to Surgery, mean(SD), days 10.7(13.3) 7.3(6.7)
0.735
3
Contralateral Carotid Stenosis (%)
0.999
1
    <50 (75) 65 10
    50-69 (11) 10 1
    ≥70 (7) 6 1
Modified Barthel Scale (mean (SD)) 19.2(1.9) 20.0(0.0)
0.113
3
Modified Rankin Score (mean (SD)) 1.4(1.1) 1.1(0.9)
0.375
3
NIHSS (mean (SD)) 1.8(2.2) 1.4(1.9)
0.642
3
SSQoL (summary) (mean (SD)) 3.7(0.9) 4.1(0.8)
0.146
2
Systolic Blood Pressure (mean (SD), mm Hg) 132.3(14.8) 132.3(18.2)
0.948
2
Diastolic Blood Pressure (mean (SD), mm Hg 77.0(10.4) 72.4(10.8)
0.163
2
PET OEF Ratio (mean(SD)) 1.25(0.13) 1.29(0.18)
0.381
2
Collateral Circulation (number of angiographic Collaterals)
0.475
1
    0 (10) 9 1
    1 (34) 31 3
    2 (42) 36 6
    3 (7) 5 2































Wilcoxon Rank Sum test
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Table 4A
Comparison of Intra-operative Data Between Those Who Did and Did Not Experience A Stroke Within Two 
Days After Surgery




        Nitrous oxide
        No 48 9 57 0.357
        Yes 33 3 36
        Halothane
        No 78 12 90 0.999
        Yes 3 0 3
        Enflurane
        No 80 12 92 0.999
        Yes 1 0 1
        Isoflurane
        No 49 7 56 0.999
        Yes 32 5 37
        Narcotic
        No 10 2 12 0.651
        Yes 71 10 81
        Relaxant
        No 11 3 14 0.382
        Yes 70 9 79
        Barbiturates
        No 53 8 61 0.999
        Yes 28 4 32
        Propofol
        No 35 2 27 0.498
        Yes 56 10 66
        Other general anesthesia
        No 28 4 32 0.999
        Yes 53 8 61
        Local anesthesia
        No 67 10 77 0.999
        Yes 13 2 15
Side of surgery
    Right 49 5 54 0.348
    Left 32 7 39
Heparin during MCA occlusion
    No 69 9 78 0.403
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Stroke No Stroke Yes Total No. of Subjects
P value
*
    Yes 12 3 15
Cerebral monitoring
    No 49 6 55 0.504
    Yes 32 6 38
        EEG
        No 1 1 2 0.295
        Yes 31 5 36
        Change during MCA occlusion
        No 28 5 33 0.999
        Yes 3 0 3
Evoked potentials
    No 18 3 21 0.999
    Yes 14 3 17
        Change during MCA occlusion
        No 13 3 16 0.999
        Yes 1 0 1
Type of anastomosis
        Interrupted
        No 21 1 22 0.282
        Yes 60 11 71
        Running
        No 67 12 79 0.202
        Yes 14 0 14
        Interrupted and running
        Yes 70 11 81 0.999
        No 11 1 12
Suture type
        Nylon 54 8 62 0.999
        Prolene 27 4 31
Suture size
        9-0 21 3 24 0.999
        10-0 60 9 69
Intraoperative bypass graft patency assessment
        Doppler 58 8 66 0.566
        Angiography 19 4 23
        Other 1 0 1
Anastomosis Patent in OR
    No 0 1 1 0.133
    Yes 76 13 89
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Stroke No Stroke Yes Total No. of Subjects
P value
*
    No data 3 3
*
P values - Fisher's exact test
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Table 4B
Comparison of Intra-operative Data Between Those Who Did and Did Not Experience A Stroke Within Two 
Days After Surgery (Continued)
Stroke Number Mean SD Minimum Maximum
P value
*
Average systolic BP during surgery (mm Hg) No 81 132.8 17.8 98 199 0.264
Yes 12 138.9 15.3 118 160
Average diastolic BP during surgery (mm Hg) No 81 66.3 9.7 40 90 0.864
Yes 12 65.8 9.2 52 80
Lowest systolic BP during surgery (mm Hg) No 81 102.1 18.3 68 177 0.064
Yes 12 112.6 15.8 95 145
Lowest diastolic BP during surgery (mm Hg) No 81 54.3 11.0 30 98 0.1186
Yes 12 58.8 9.7 40 78
Duration of lowest BP during surgery (minutes) No 79 8.3 9.9 0 54 0.807
Yes 12 7.6 5.6 1 20
Duration of MCA occlusion (minutes) No 78 45.4 24.2 15 123 0.182
Yes 11 55.9 25.3 26 99
Average systolic BP during MCA occlusion (mm Hg) No 78 136.2 20.9 95 190 0.572
Yes 11 140 20.7 106 175
Average diastolic BP During MCA occlusion (mm Hg) No 78 67.5 11.4 40 100 0.561
Yes 11 69.7 15.3 55 110
Heparin dose No 12 2500.8 2032.7 10 7500 0.704
Yes 3 3000 1732.1 2000 5000
Protamine dose Not used
Diameter of STA (mm) No 79 1.6 0.7 1 4 0.178
Yes 12 1.9 0.5 1 3
Diameter of MCA cortical branch (mm) No 79 1.5 0.6 1 3 0.105
Yes 12 1.8 0.5 1 3
*
P values - t-tests
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